Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

BioPharma Terug naar discussie overzicht

NASH - bedrijven

65 Posts
Pagina: «« 1 2 3 4 | Laatste | Omlaag ↓
  1. Wil Helmus 25 april 2019 14:53
    Press Releases

    April 25, 2019

    Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)

    FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 25, 2019-- Gilead Sciences, Inc.(Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a = 1-stage histologic improvement in fibrosis without worsening of NASH.

    In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a = 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo. Selonsertib was generally well tolerated and safety results were consistent with prior studies.

    “While we had hoped for different outcomes from the STELLAR program, we remain focused and committed to developing highly effective treatments for patients living with advanced fibrosis due to NASH. We are actively exploring the STELLAR data and will work with external collaborators like PathAI and insitro, to further our understanding of this complex disease and advance our development programs. We thank the patients and their physicians who participated in the STELLAR program for contributing to these efforts,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “We believe that effective therapy for NASH will ultimately require a combination approach that targets distinct pathways involved in the pathogenesis of this disease. In this regard, we look forward to data from the Phase 2 ATLAS combination trial of selonsertib, cilofexor and firsocostat in patients with advanced fibrosis due to NASH, which will be available later this year.”

    Gilead will now work with the Data Monitoring Committee and investigators to conclude the STELLAR-3 study in a manner consistent with the best interests of each patient.

    Selonsertib, cilofexor, and firsocostat, alone or in combination, are investigational compounds and are not approved by the U.S. Food & Drug Administration (FDA) or any other regulatory authority. Safety and efficacy have not been established for these agents.

65 Posts
Pagina: «« 1 2 3 4 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.530
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.961
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.808
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.783
Aedifica 3 925
Aegon 3.258 323.009
AFC Ajax 538 7.088
Affimed NV 2 6.303
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.250
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.110
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.644
AMG 971 134.105
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.032
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.346
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.580
ASR Nederland 21 4.506
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.739
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.439

Macro & Bedrijfsagenda

  1. 17 maart

    1. Detailhandelsverkopen januari/februari (Chi)
    2. Industriële productie januari/februari (Chi)
    3. Internationale handel januari (NL)
    4. Empire State index maart (VS)
    5. Detailhandelsverkopen februari (VS)
    6. Bedrijfsvoorraden januari (VS)
    7. Vertrouwen huizenbouwers maart (VS)
    8. Fountain Q4-cijfers
  2. 18 maart

    1. B&S Group Q4-cijfers
    2. ZEW economisch sentiment maart (VS) volitaliteit verwacht
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht